Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 1.00 |
| ▸ | P2RY1 | P47900 | 4/20 | 1.00 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | P2RX3 | P56373 | 3/20 | 1.00 |
| ▸ | P2RX7 | Q99572 | 3/20 | 1.00 |
| ▸ | P2RX5 | Q93086 | 2/20 | 1.00 |
| ▸ | P2RX4 | Q99571 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | CASP1 | P29466 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | CASP7 | P55210 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.86 |
| ▸ | HPGD | P15428 | 2/20 | 0.86 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.86 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.86 |
| ▸ | P2RY13 | Q9BPV8 | 4/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31236767 | 1.00 | MAPT (1.00) | MAPTTDP1P2RY1P2RX2KDM4E | |
| SCHEMBL5287746 | 1.00 | MAPT (1.00) | MAPTTDP1P2RY1P2RX2KDM4E | |
| SCHEMBL7196930 | 1.00 | MAPT (1.00) | MAPTTDP1P2RY1P2RX2KDM4E | |
| SCHEMBL7196945 | 1.00 | MAPT (1.00) | MAPTTDP1P2RY1P2RX2KDM4E | |
| SCHEMBL13624677 | 1.00 | MAPT (1.00) | MAPTTDP1P2RY1P2RX2KDM4E | |
| Isoppads SCHEMBL29494952 | 0.93 | MAPT (1.00) | MAPTTDP1P2RY1P2RX2KDM4E | |
| Isoppads SCHEMBL14702227 | 0.93 | MAPT (1.00) | MAPTTDP1P2RY1P2RX2KDM4E | |
| SCHEMBL16450980 | 0.89 | MAPT (0.79) | MAPTTDP1P2RY1P2RX2KDM4E | |
| SCHEMBL29374112 | 0.88 | MAPT (0.78) | MAPTTDP1P2RY1P2RX2KDM4E | |
| SCHEMBL15354624 | 0.86 | MAPT (0.76) | MAPTTDP1P2RY1P2RX2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4426280-B1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | GURBA ALEXANDRE (CH) | 2026-03-18 | — | — | EP | claimed |
| WO-2025229484-A1 | PURINERGIC P2 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF CONGENITAL SIDEROBLASTIC ANEMIAS | UNIVERSITÀ DEGLI STUDI DI BARI ALDO MORO (IT) | 2025-11-06 | — | — | WO | claimed |
| WO-2025082702-A1 | METHODS FOR IDENTIFYING AND STRATIFYING CANCERS AND CANCER PATIENTS BASED ON P2X4 RECEPTOR EXPRESSION | Johann Wolfgang Goethe-Universität Frankfurt am Main (DE) | 2025-04-24 | — | — | WO | claimed |
| EP-4542231-A1 | METHODS FOR IDENTIFYING AND STRATIFYING CANCERS AND CANCER PATIENTS BASED ON P2X4 RECEPTOR EXPRESSION | Johann-Wolfgang-Goethe-Universität Frankfurt am Main (DE) | 2025-04-23 | — | — | EP | claimed |
| WO-2025073290-A1 | VPS4 INHIBITORS AND METHODS OF USE THEREOF | PARA THERAPEUTICS, INC. (US) | 2025-04-10 | — | — | WO | claimed |
| US-20250057791-A1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | GURBA ALEXANDRE (CH) | 2025-02-20 | — | — | US | claimed |
| US-20240358663-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-10-31 | — | — | US | claimed |
| EP-4426280-A1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | Gurba, Alexandre (CH) | 2024-09-11 | — | — | EP | claimed |
| US-20240252600-A1 | COMPOSITIONS AND METHODS FOR PROMOTING THE MINERALIZATION OF BIOLOGICAL TISSUE | NEW YORK SOCIETY FOR THE RELIEF OF THE RUPTURED AND CRIPPLED, MAINTAINING THE HOSPITAL FOR SPECIAL SURGERY | 2024-08-01 | — | — | US | claimed |
| US-20240075036-A1 | THERAPEUTIC COMBINATIONS INCLUDING INHIBITORS OF THE P2X4 RECEPTOR FOR TREATING AND PREVENTING PROLIFERATIVE DISORDERS | CHEMOTHERAPEUTISCHES FORSCHUNGSINSTITUT GEORG-SPEYER-HAUS (DE) | 2024-03-07 | — | — | US | claimed |
| WO-2023111938-A1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | GURBA, Alexandre (CH) | 2023-06-22 | — | — | WO | claimed |
| EP-4197533-A1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | Guerin, Patrick (CH) | 2023-06-21 | — | — | EP | claimed |
| US-20230077514-A1 | METHODS FOR MODULATING CALORIE CONSUMPTION | UNIV DUKE (US) | 2023-03-16 | — | — | US | claimed |
| US-20230022922-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2023-01-26 | — | — | US | claimed |
| US-20220363709-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2022-11-17 | — | — | US | claimed |
| WO-2022195066-A1 | THERAPEUTIC COMBINATIONS INCLUDING INHIBITORS OF THE P2X4 RECEPTOR FOR TREATING AND PREVENTING PROLIFERATIVE DISORDERS | CHEMOTHERAPEUTISCHES FORSCHUNGSINSTITUT GEORG-SPEYER-HAUS (DE) | 2022-09-22 | — | — | WO | claimed |
| EP-4059495-A1 | THERAPEUTIC COMBINATIONS INCLUDING INHIBITORS OF THE P2X4 RECEPTOR FOR TREATING AND PREVENTING PROLIFERATIVE DISORDERS | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus (DE) | 2022-09-21 | — | — | EP | claimed |
| WO-2022086892-A1 | INTERLEUKIN 4 (IL4)-INDUCED GENE 1 INHIBITORS AND METHODS OF USE THEREOF | CALITHERA BIOSCIENCES, INC. (US) | 2022-04-28 | — | — | WO | claimed |
| EP-3986894-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | Calithera Biosciences, Inc. (US) | 2022-04-27 | — | — | EP | claimed |
| WO-2022051420-A1 | METHODS AND COMPOSITIONS FOR TARGETING CYTOSOLIC DSDNA SIGNALING IN CHROMOSOMALLY UNSTABLE CANCERS | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-03-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363709-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | MAPT 4512/4885TDP1 504/4885P2RY1 21/4885 |
| US-20230022922-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | MAPT 4512/4885TDP1 504/4885P2RY1 21/4885 |
| US-20240358663-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | VASP, MYLK, EDNRB | MAPT 4064/4885TDP1 2465/4885P2RY1 141/4885 |
| US-20250057791-A1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | P2RX2, P2RX3, P2RX1 | MAPT 4817/4885TDP1 3625/4885P2RY1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.